Opens new window
  
HomeAbout MCANProgram SitesSpecial ProjectsResources
Merck Childhood Asthma Network

Merck Childhood Asthma Network

1400 K Street, NW
Suite 750
Washington, DC 20005

T: (202) 326-5200
F: (202) 326-5201





Jeffrey L. Sturchio, PhD
Vice President
Corporate Responsibility
Merck & Co., Inc.

 

Dr. Jeffrey L. Sturchio is Vice President, Corporate Responsibility, at Merck & Co., Inc., in Whitehouse Station, New Jersey, where he manages a portfolio of activities including The Merck Company Foundation/Corporate Contributions, the Merck Institute for Science Education, the Merck Childhood Asthma Network, global health partnerships (including the Merck MECTIZAN Donation Program), global HIV/AIDS access programs, corporate responsibility communications and the Merck Archives.

 

Since 2000, Dr. Sturchio has been centrally involved in Merck’s participation in the UN/Industry Accelerating Access Initiative to help improve HIV/AIDS care and treatment in the developing world.  He is also a member of the private sector delegation to the Board of the Global Fund to Fight AIDS, TB and Malaria and serves as Vice-Chair of the Corporate Council on Africa.

 

Dr. Sturchio received an A.B. in history (1973) from Princeton University and a Ph.D. in the history & sociology of science from the University of Pennsylvania (1981).  His previous positions include the AT&T Archives, the Beckman Center for the History of Chemistry at the University of Pennsylvania, Rutgers University, and the New Jersey Institute of Technology.  He has also been a Postdoctoral Fellow and Senior Fellow at the Smithsonian Institution's National Museum of American History (NMAH).  In 2004 he was appointed a Visiting Fellow of LSE Health and Social Care at the London School of Economics and elected a Fellow of the American Association for the Advancement of Science.  He joined Merck in June 1989 as the Company’s first Corporate Archivist.

 

His publications include Chemistry in America, 1876-1976: Historical Indicators (Reidel, 1985; paperback edition, 1988), written with A. Thackray, P. T. Carroll, and R. F. Bud; Values & Visions: A Merck Century (Merck & Co., Inc., 1991); “Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation” (with L. Galambos), Business History Review 72 (Summer 1998): 250-278; “Against:  Direct to consumer advertising is medicalising normal human experience” (with S. Bonaccorso), British Medical Journal 324 (13 April 2002): 910-911; “Successful public-private partnerships in global health: lessons from the MECTIZAN Donation Program,” (with B. Colatrella), in The Economics of Essential Medicines, ed. by B. Granville (London:  Royal Institute of International Affairs, 2002); and “Partnership for action: the experience of the Accelerating Access Initiative, 2000-04, and lessons learned,” in Delivering Essential Medicines, ed. by A. Attaran and B. Granville (London: Royal Institute of International Affairs, 2004).


Printer Friendly Page
 

Floyd J. Malveaux, MD, PhD
Executive Director

Evalyn N. Grant, MD
U.S. Regional Director
Respiratory Scientific Affairs
Merck & Co., Inc.

Leona E. Markson, ScD
Executive Director
Outcomes Research & Management
Merck & Co., Inc.

Richard K. Murray, MD
Vice President
External Medical & Scientific Affairs
Merck & Co., Inc.

Nancy C. Santanello, MD, MS
Vice President
Epidemiology
Merck & Co., Inc.

Jeffrey L. Sturchio, PhD
Vice President
Corporate Responsibility
Merck & Co., Inc.

 
Site Map Privacy Policy Terms of Use Copyright MCAN 2006-2008